Merrill: Confidence...
Health Care: Drugs
Geron Corporation (GERN: NASDAQ)
$1.12 0.00 | 0.00%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 22.06M | 16.10M | 45.97M | 34.60M |
| Receivables | 752.00K | 1.40M | 1.80M | 1.32M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.34M | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 98.42M | 125.62M | 195.02M | 117.78M |
| Property, Plant & Equipment, Gross | 13.45M | 18.54M | 18.00M | 22.41M |
| Accumulated Depreciation & Depletion | 12.48M | 17.30M | 14.91M | 18.47M |
| Property, Plant & Equipment, Net | 974.00K | 1.24M | 3.09M | 3.94M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 410.00K | 33.18M | 35.48M | 58.66M |
| Total Non-Current Assets | 1.38M | 34.42M | 38.57M | 62.60M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 99.80M | 160.05M | 233.58M | 180.38M |
| Accounts Payable | 3.43M | 2.98M | 3.46M | 2.18M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 51.00K | 64.00K | 28.21M | 897.00K |
| Total Current Liabilities | 14.15M | 13.44M | 40.85M | 7.46M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 350.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 350.00K |
| Total Liabilities | 14.15M | 13.44M | 40.85M | 7.80M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 85.65M | 146.60M | 192.74M | 172.58M |
| Common Par | 130.00K | 131.00K | 123.00K | 92.00K |
| Additional Paid In Capital | 939.87M | 932.07M | 881.36M | 750.16M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -854.38M | -785.50M | -688.65M | -577.27M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 40.00K | -91.00K | -96.00K | -406.00K |
| Total Capitalization | 85.65M | 146.60M | 192.74M | 172.58M |
| Total Equity | 85.65M | 146.60M | 192.74M | 172.58M |
| Total Liabilities & Stock Equity | 99.80M | 160.05M | 233.58M | 180.38M |
| Total Common Shares Outstanding | 130.24M | 131.44M | 122.62M | 92.52M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 126.94M | 124.51M | 97.60M | 88.08M |
| Diluted Weighted Shares Outstanding | 126.94M | 124.51M | 97.60M | 88.08M |
| Number of Employees | 105 | 178 | 175 | 172 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with GERN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- ContributorUnder-$10 Setting Up To Tra...
- ContributorStocks Under-$10 Moving Hig...
Latest GERN Headlines from TheStreet
- 8 Stocks Under $10 Soaring Higher 01.31.13 | 03:01 pm
- 5 Stocks Ready to Break Out 01.18.13 | 12:01 pm
- Stocks Slump as U.S. and Eurozone Uncertainties Fester 12.04.12 | 04:12 pm
- Stock Futures Point to Slightly Higher Wall Street Open 12.04.12 | 09:12 am
- Stocks to Watch: Oracle, Geron, Knight, Big Lots (Update 1) 12.04.12 | 07:12 am
- Morning Briefing: 10 Things You Should Know 12.04.12 | 06:12 am
- A Weak Open On Wall Street As China Stumbles 09.10.12 | 04:09 pm
- Geron's CEO Presents At Update On Imetelstat Clinical Development Program Conference (Transcript) 09.10.12 | 02:09 pm
- Geron Stung by Cancer Drug Blowup 09.10.12 | 08:09 am
- 5 Biotech Stocks Under $5 Blasting Off 08.16.12 | 03:08 pm
Press Releases for GERN
- Geron Initiates Phase 2 Trial Of GRN1005 In Brain Metastases From Breast Cancer - Business Wire 12.12.11 | 07:12 am
- Geron Presents Final Phase 1 Clinical Data On GRN1005 At AACR-NCI-EORTC - Business Wire 11.15.11 | 07:11 am
- Geron To Focus On Its Novel Cancer Programs - Business Wire 11.14.11 | 04:11 pm
- Geron Corporation Reports 2011 Third Quarter Financial Results And Events - Business Wire 11.03.11 | 04:11 pm
- Geron Announces Conference Call To Discuss Third Quarter Financial Results And Highlights - Business Wire 10.25.11 | 04:10 pm
- Geron Announces Presentation At ECTRIMS/ACTRIMS - Business Wire 10.25.11 | 07:10 am
- Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial - Business Wire 10.20.11 | 07:10 am
- Geron Corporation Appoints John A. Scarlett As Chief Executive Officer And Director - Business Wire 09.29.11 | 05:09 pm
- Geron To Webcast Presentations At Upcoming Investor Conferences - Business Wire 09.12.11 | 07:09 am
- Geron Corporation Reports 2011 Second Quarter Financial Results And Events - Business Wire 07.28.11 | 04:07 pm
Partner Headlines for GERN
- Morning Market Losers - Benzinga 12.04.12 | 09:12 am
- Geron Posts Narrower Loss - Analyst Blog - Zacks 10.31.12 | 09:10 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Geron Hit by Pipeline Setback - Analyst Blog - NASDAQ 09.11.12 | 09:09 pm
- Morning Market Losers - Benzinga 09.10.12 | 09:09 am
- UPDATE: Stifel Nicolaus Initiates Geron Corporation at Buy with $4 PT; Oncology Refocus Paying Off - Benzinga 08.30.12 | 12:08 pm
- Geron Posts In-Line Loss - Analyst Blog - Zacks 08.01.12 | 09:08 am
- Ford and 3 Stocks INITIATED at These Levels Today - Wall St. Cheat Sheet 06.28.12 | 03:06 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Neutral on Geron Corp. - Analyst Blog - Zacks 04.02.12 | 07:04 pm
